Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7SCF

M. tb EgtD in complex with HD2

7SCF の概要
エントリーDOI10.2210/pdb7scf/pdb
分子名称Histidine N-alpha-methyltransferase, (2S)-3-(1H-imidazol-5-yl)-2-(1H-pyrrol-1-yl)propanoic acid, DI(HYDROXYETHYL)ETHER, ... (6 entities in total)
機能のキーワードergothioneine biosynthesis pathway, rossmann fold domain, histidine/histamine derivatives, sam dependent methyltransferase, transferase
由来する生物種Mycobacterium tuberculosis
タンパク質・核酸の鎖数2
化学式量合計72489.36
構造登録者
Sudasinghe, T.D.,Ronning, D.R. (登録日: 2021-09-28, 公開日: 2021-12-01, 最終更新日: 2023-10-18)
主引用文献Sudasinghe, T.D.,Banco, M.T.,Ronning, D.R.
Inhibitors of Mycobacterium tuberculosis EgtD target both substrate binding sites to limit hercynine production.
Sci Rep, 11:22240-22240, 2021
Cited by
PubMed Abstract: Ergothioneine (EGT) is a low molecular weight histidine betaine essential in all domains of life but only synthesized by selected few organisms. Synthesis of EGT by Mycobacterium tuberculosis (M. tb) is critical for maintaining bioenergetic homeostasis and protecting the bacterium from alkylating agents, oxidative stress, and anti-tubercular drugs. EgtD, an S-adenosylmethionine-dependent methyltransferase (AdoMet), catalyzes the trimethylation of L-Histidine to initiate EGT biosynthesis and this reaction has been shown to be essential for EGT production in mycobacteria and for long-term infection of murine macrophages by M. tb. In this work, library screening and structure-guided strategies identified multiple classes of M. tb EgtD inhibitors that bind in various regions of the enzyme active site. X-ray crystal structures of EgtD-inhibitor complexes confirm that L-Histidine analogs bind solely to the L-Histidine binding site while drug-like inhibitors, such as TGX-221, and S-Glycyl-H-1152 span both the L-Histidine and AdoMet binding sites. These enzyme-inhibitor complexes provide detailed structural information of compound scaffolds useful for developing more potent inhibitors that could shorten Tuberculosis treatment regimens by weakening important bacterial defenses.
PubMed: 34782676
DOI: 10.1038/s41598-021-01526-6
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.67 Å)
構造検証レポート
Validation report summary of 7scf
検証レポート(詳細版)ダウンロードをダウンロード

248335

件を2026-01-28に公開中

PDB statisticsPDBj update infoContact PDBjnumon